Coherus Oncology
CHRS
124 hedge funds and large institutions have $90.5M invested in Coherus Oncology in 2024 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 35 closing their positions.
4,679% more call options, than puts
Call options by funds: $7.36M | Put options by funds: $154K
13% more capital invested
Capital invested by funds: $79.9M → $90.5M (+$10.6M)
3% less funds holding
Funds holding: 128 → 124 (-4)
9.85% less ownership
Funds ownership: 66.79% → 56.94% (-9.8%)
11% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 35
12% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.93M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.46M |
| 3 |
Morgan Stanley
New York
|
+$1.44M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$601K |
| 5 |
Millennium Management
New York
|
+$283K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$5.77M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.21M |
| 3 |
Barclays
London,
United Kingdom
|
-$2.43M |
| 4 |
Goldman Sachs
New York
|
-$1.73M |
| 5 |
BlackRock
New York
|
-$983K |
CHRS Hedge Fund Activity: Q4 2024 in Review
124 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2024, worth a combined $90.5M — up 13% from $79.9M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of CHRS and 31 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 30 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $5.93M. The largest seller was Rubric Capital Management (New York), cutting an estimated $5.77M.
- 124 institutional investors held Coherus Oncology (CHRS) as of Q4 2024, down from 128 in Q3 2024.
- Funds reported $90.5M of Coherus Oncology stock for Q4 2024, up 13% quarter-over-quarter.
- 31 funds opened new Coherus Oncology positions in Q4 2024 and 35 closed out, a net change of -4 holders.
- The largest Coherus Oncology buyer in Q4 2024 was Point72 Asset Management, an estimated $5.93M added.
- The largest Coherus Oncology seller in Q4 2024 was Rubric Capital Management (New York), an estimated $5.77M sold.
Based on aggregated 13F filings for Q4 2024.